The world's only vaccine to prevent Hepatitis E, Hecolin® was launched in October 2012.
The first viral vaccine developed with E. coli expression system, completely reversed the global academic community's perception that “the prokaryotic system cannot be used for viral vaccines development”.
Proven its safety, immunogenicity and efficacy in over 100,000 adults in clinical trials.
Hecolin® was approved for clinical trials in the U.S.A. in early 2019 and the Phase I clinical trials were completed in 2020. It is the first Chinese vaccine product for which clinical trials were conducted in the U.S.A. In 2020, Hecolin® was approved for marketing in Pakistan and has since then contributed to the prevention of hepatitis E in Pakistan.
Hepatitis E is an acute infectious disease transmitted through the fecal-oral route by contacting or consumption of food contaminated with hepatitis E viruses. The disease is widespread mainly in developing countries and regions in the Indian Subcontinent, Africa and South America. It is one of the major hepatitis in developing countries today seriously endangering human health, and its incidence has been rapidly increasing in recent years. Availability of Hecolin® enables people in countries with hepatitis E outbreaks to benefit from the biotechnological innovations of China.
闽公网安备 35020502000554号